Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists are looking for a drug that improves overall survival better than the current clinical gold standard (Eli Lilly's Gemzar plus Genentech's Tarceva regimen). With a five-year survival rate of less than 5%, pancreatic cancer is one of the most lethal carcinomas. Of the late-stage drugs and immunotherapies currently in the drug pipeline, vaccines seem to offer the most promise of improving survival rates in the short- to medium- term, while epidermal growth factor receptor (EGFR) inhibitors may augment combination therapy regimens. Most of the emerging therapies are being investigated in combination with agents already approved for use in pancreatic cancer-primarily Gemzar.
"Gemzar will continue to dominate the market in terms of patient share, even after its loss of patent protection, thanks to these pivotal roles and its high price compared with the previous standard in pancreatic cancer, 5-FU treatment," said Mary Argent-Katwala, Ph.D., director at Decision Resources. "Strengthening this, regardless of stage at diagnosis, many patients will be treated with Gemzar throughout their disease course."
According to the new report entitled Pancreatic Cancer (Advanced): Physicians Desperate for a Drug that Shows a Significant Increase in Survival, experts are cautiously optimistic over the prospects for therapeutic vaccines in the treatment of advanced pancreatic cancer. Their views are based on the fact that vaccines are well tolerated and therefore have the potential to be used in patients who are unfit to receive cytotoxic therapy. While emerging vaccines have shown safety advantages over current therapies, none will have better efficacy than the current gold standard. However, with the launch of Pharmexa's GV-1001 and Cell Genesys's GVAX therapeutic vaccines will add $700 million combined sales to the 2016 advanced pancreatic cancer market.
About the Report
Pancreatic Cancer (Advanced): Physicians Desperate for a Drug that Shows a Significant Increase in Survival is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/